All articles tagged with #puberty blockers
Health Secretary Wes Streeting has approved a clinical trial for puberty blockers in children with gender dysphoria, despite personal discomfort and opposition from some politicians, following recommendations from the Cass Review to better research the drugs' effects.
The UK has indefinitely banned new prescriptions of puberty blockers for minors with gender dysphoria, following an independent study that highlighted weak medical evidence and potential safety risks. The decision, supported by the study's author, Dr. Hilary Cass, emphasizes the need for evidence-led children's healthcare. Transgender activists have criticized the ban, which allows current users to continue treatment and permits prescriptions for cisgender minors with early puberty. The ban will be reviewed in 2027, as the UK plans clinical trials on the medication.
The United Kingdom has indefinitely banned the use of puberty blockers for teenagers, marking a significant shift in health policy regarding gender dysphoria treatment for minors.
The UK government has banned the use of puberty blockers for individuals under the age of 18, marking a significant shift in health policy regarding gender identity treatments for minors. This decision reflects ongoing debates about the appropriateness and safety of such medical interventions for young people.
The Supreme Court is set to hear a case regarding the legality of state bans on gender transition medical treatments, such as puberty blockers and hormones, for transgender teens. The case, brought by three transgender teens, their parents, and a doctor, seeks to ensure access to what they argue is essential healthcare.
A preprint study from Mayo Clinic suggests that puberty blockers may cause long-term fertility problems in boys with gender dysphoria, potentially leading to permanent impacts such as sex gland atrophy and testicular microlithiasis. The study raises concerns about the use of puberty-blocking drugs, linking them to increased risks of testicular cancer and other health issues. Experts caution against the growing rush to gender-affirming treatments, emphasizing the need for safer and more effective approaches for those with gender dysphoria.
Jocelyn Claire Reed, a 24-year-old trans woman, believes that receiving puberty blockers as a child could have prevented the physical changes of male puberty, which she now seeks to reverse through hormone replacement therapy and gender-affirming treatment. The highly-anticipated Cass Review, led by Dr. Hilary Cass, has made 32 recommendations to overhaul NHS trans services, including the need for clearer guidelines on social transitioning in schools and greater mental health support for trans children. The report also emphasizes the importance of holistic care, research, and age-appropriate approaches in gender care for children and young people questioning their gender identity.
England's NHS has decided to stop routinely prescribing puberty blockers to children with gender dysphoria due to limited evidence of their safety and effectiveness. The decision has been praised by detransitioners who have experienced negative effects from such treatments, with one calling it a matter of "common sense." However, a U.K.-based charity supporting transgender children has expressed disappointment, while detransitioners have shared their experiences of enduring lasting side effects from puberty blockers.
England's National Health Service (NHS) has ceased prescribing puberty blockers for children and young people with gender dysphoria, citing insufficient evidence of safety and clinical effectiveness. The decision, condemned by LGBTQ groups, limits access to puberty blockers to clinical research trials and some private clinics, sparking criticism and concern from advocates. Meanwhile, in the US, major medical associations support gender-affirming care for trans youth, including the use of puberty blockers, emphasizing its potential life-saving impact.
England's NHS has halted the use of puberty blockers for transgender minors due to insufficient evidence of safety and effectiveness, pending a study to be conducted by December. While less than 100 young people in England are currently prescribed puberty blockers and will be able to continue their treatments, clinicians can still apply for the treatment under NHS England's Individual Funding Request process. The decision has sparked debate over the risks and benefits of gender-affirming care, with major medical associations in the U.S. emphasizing its safety and effectiveness, while some states have restricted gender-affirming care for transgender youth.
Former UK Prime Minister Liz Truss praised England's ban on puberty blockers for children, citing concerns about long-term impacts on fertility and overall health. The National Health Service (NHS) banned the use of puberty blockers for children, citing safety concerns and limited research on the long-term effects, and it will now only be available to children in limited ways, such as clinical trials. Truss expressed concerns about the pressure from gender ideologues and the impact on teenage girls, emphasizing the need to protect single-sex spaces. Mental health nurse Amy Gallagher echoed Truss' sentiment, warning about irreversible side effects for kids and emphasizing the lack of research on the safety of these hormones.
The UK's National Health Service has announced a ban on the prescription of puberty blockers to minors under 18, except in regulated clinical trials, following a review that found a lack of consensus and open dialogue about gender dysphoria. The decision comes amid a significant increase in referrals to the Gender Identity Development Service, with fewer than 100 children currently on puberty blockers continuing their treatment. The move has sparked debate and protests, with concerns raised about the lack of evidence supporting hormonal treatment for minors and the long-term effects of puberty blockers.
England's National Health Service has banned the use of puberty blockers for children seeking treatment for gender dysphoria due to limited research on safety and clinical effectiveness. The decision comes after concerns about the drugs' impact on mental health, with a study showing that one-third of trans youth experienced a decline while taking puberty blockers. Some European countries have also exercised caution on using pharmaceutical interventions for children diagnosed with gender dysphoria, with Swedish doctors calling for more research on the long-term effects of these drugs.
NHS England has announced that children with gender dysphoria will no longer be prescribed puberty blockers due to insufficient evidence of their safety and clinical effectiveness. The decision follows a public consultation and review of available evidence, with new regional services for under-18s with gender dysphoria set to open next month without the use of puberty blockers, except for those participating in clinical trials. The move has been welcomed by the government but has raised concerns from LGBTQ+ rights groups and praise from organizations advocating evidence-based policymaking in gender identity services.
NHS England has announced that trans youth will no longer be prescribed puberty blockers at gender identity clinics, except as part of clinical research trials, which has been met with disappointment from trans youth charity Mermaids. The decision is seen as a blow to access to gender-affirming healthcare in England, with concerns raised about the impact on trans youth waiting for treatment. The move comes amid broader changes in trans healthcare in the UK, including the planned closure of the Tavistock clinic and its replacement with regional service centers.